Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoonRISe-3: TAR-210 vs intravesical chemotherapy in high-risk non-muscle-invasive bladder cancer with FGFR alterations
jRCT2011250030Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of Erda-iDRS in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Disease-free Survival. Started Dec 2025; status: recruiting.
02
Drugs
Erda-iDRS
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on jRCT2011250030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250030.